Literature DB >> 28787333

Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients.

Kazunaga Ishigaki1, Yousuke Nakai, Hiroyuki Isayama, Kei Saito, Tsuyoshi Hamada, Naminatsu Takahara, Suguru Mizuno, Dai Mohri, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Minoru Tada, Kazuhiko Koike.   

Abstract

OBJECTIVES: Pancreatic cancer is reported to be highly associated with thromboembolism (TE). The aim of this analysis is to clarify risk factors for TE and its clinical impact in Japanese patients with pancreatic cancer.
METHODS: Data on consecutive pancreatic cancer patients receiving systemic chemotherapy between August 1999 and July 2015 were retrospectively studied. Both symptomatic and asymptomatic, arterial and venous TEs were included in the analysis. Risk factors for TE development were analyzed using a proportional hazards model with death without TE as a competing risk. The impact of TE on survival was also evaluated using a time-dependent covariate multiple Cox model.
RESULTS: A total of 475 patients were included in the analysis, and 57 TEs (12%) were identified: 45 venous TEs and 12 arterial TEs. The median time to TE was 169 days and the median survival from TE was 65 days. Liver metastasis was the only significant risk factor for TE (subdistribution hazards ratio, 2.15; P = 0.01), and TE was significantly associated with poor prognosis (hazards ratio, 3.31; P < 0.01).
CONCLUSIONS: Thromboembolism was not uncommon in Japanese patients receiving chemotherapy for advanced pancreatic cancer and was associated with poor prognosis. Liver metastasis was the risk factor for TE.

Entities:  

Mesh:

Year:  2017        PMID: 28787333     DOI: 10.1097/MPA.0000000000000889

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Impact of pulmonary embolism on morbidity and mortality in patients undergoing pancreatic surgery.

Authors:  Benjamin Müssle; Nathalie Buck; Stephanie Schade; Marian Sommer; Florian Oehme; Andreas Bogner; Sebastian Hempel; Christoph Radosa; Christoph Kahlert; Marius Distler; Jürgen Weitz; Thilo Welsch
Journal:  Langenbecks Arch Surg       Date:  2020-10-09       Impact factor: 3.445

Review 2.  The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues.

Authors:  Elena Campello; Anton Ilich; Paolo Simioni; Nigel S Key
Journal:  Br J Cancer       Date:  2019-07-22       Impact factor: 7.640

3.  Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.

Authors:  Li-Peng Zhang; Hu Ren; Yong-Xing Du; Cheng-Feng Wang
Journal:  World J Gastroenterol       Date:  2020-12-14       Impact factor: 5.742

4.  Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma.

Authors:  Renata Talar-Wojnarowska; Małgorzata Woźniak; Anna Borkowska; Katarzyna Cypryk; Marek Olakowski; Ewa Małecka-Panas
Journal:  Medicina (Kaunas)       Date:  2020-12-09       Impact factor: 2.430

5.  Venous Thromboembolism in Japanese Patients With Pancreatic Cancer.

Authors:  Takahito Suzuki; Reina Hori; Kazutaka Takeuchi; Ryo Yamamura; Hiromasa Katoh; Yoshihiro Noji; Masato Yamaguchi; Susumu Fujino
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

6.  Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis.

Authors:  Yajuan Lv; Yong Hou; Bo Pan; Yuwan Ma; Paiyun Li; Lili Yu; Deguo Xu; Juanjuan Song; Heli Shang; Hongyan Wang; Yuan Tian
Journal:  Oncotarget       Date:  2018-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.